Cargando…

Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador, Fernando, Lucas-Dato, Ana, Roure, Silvia, Arsuaga, Marta, Pérez-Jacoiste, Asunción, García-Rodríguez, Magdalena, Pérez-Molina, José A., Buonfrate, Dora, Saugar, José María, Molina, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308528/
https://www.ncbi.nlm.nih.gov/pubmed/34199000
http://dx.doi.org/10.3390/pathogens10070812
_version_ 1783728302279622656
author Salvador, Fernando
Lucas-Dato, Ana
Roure, Silvia
Arsuaga, Marta
Pérez-Jacoiste, Asunción
García-Rodríguez, Magdalena
Pérez-Molina, José A.
Buonfrate, Dora
Saugar, José María
Molina, Israel
author_facet Salvador, Fernando
Lucas-Dato, Ana
Roure, Silvia
Arsuaga, Marta
Pérez-Jacoiste, Asunción
García-Rodríguez, Magdalena
Pérez-Molina, José A.
Buonfrate, Dora
Saugar, José María
Molina, Israel
author_sort Salvador, Fernando
collection PubMed
description Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
format Online
Article
Text
id pubmed-8308528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83085282021-07-25 Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol Salvador, Fernando Lucas-Dato, Ana Roure, Silvia Arsuaga, Marta Pérez-Jacoiste, Asunción García-Rodríguez, Magdalena Pérez-Molina, José A. Buonfrate, Dora Saugar, José María Molina, Israel Pathogens Study Protocol Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. MDPI 2021-06-27 /pmc/articles/PMC8308528/ /pubmed/34199000 http://dx.doi.org/10.3390/pathogens10070812 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Study Protocol
Salvador, Fernando
Lucas-Dato, Ana
Roure, Silvia
Arsuaga, Marta
Pérez-Jacoiste, Asunción
García-Rodríguez, Magdalena
Pérez-Molina, José A.
Buonfrate, Dora
Saugar, José María
Molina, Israel
Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_full Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_fullStr Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_full_unstemmed Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_short Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
title_sort effectiveness and safety of a single-dose ivermectin treatment for uncomplicated strongyloidiasis in immunosuppressed patients (immunostrong study): the study protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308528/
https://www.ncbi.nlm.nih.gov/pubmed/34199000
http://dx.doi.org/10.3390/pathogens10070812
work_keys_str_mv AT salvadorfernando effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT lucasdatoana effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT rouresilvia effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT arsuagamarta effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT perezjacoisteasuncion effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT garciarodriguezmagdalena effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT perezmolinajosea effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT buonfratedora effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT saugarjosemaria effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol
AT molinaisrael effectivenessandsafetyofasingledoseivermectintreatmentforuncomplicatedstrongyloidiasisinimmunosuppressedpatientsimmunostrongstudythestudyprotocol